期刊文献+

抑制CDC25A表达的siRNA真核表达载体的构建

Construction of eukaryotic expression vector of siRNA-inhibited CDC25A expression
下载PDF
导出
摘要 目的在哺乳动物细胞中构建并鉴定抑制CDC25A表达的siRNA真核表达载体。方法根据CDC25A的基因序列,设计特异性的siRNA,将合成的siRNA核酸片段退火形成双链后连接到经Bam HI和HindⅢ双酶切后的psilencer4.1真核表达载体,命名为psilencer4.1-CDC25A以及psilencer4.1-Control,并进行酶切及测序鉴定。结果通过酶切鉴定和序列测定,成功地构建出抑制CDC25A表达的siRNA载体及其阴性对照载体。结论成功构建和验证了siRNA真核表达载体,为下一步研究奠定了良好的基础。 Objective To construct and identify an eukaryotic expression vector of siRNA-inhibited CDC25A expression in mammalian cells. Methods CDC25A-specific siRNA was designed and synthesized according to the sequence of CDC25A. After annealing the nucleic acid fragment of the siRNA to form the double-stranded, they were connected with the eukaryotic expression vector psilencer4. 1 which was pre-digested with Barn HI and Hind Ⅲ. Then the constructed vectors, named psilencer4. 1-CDC25A and psilencer4. 1-Control, were digested and sequenced. Results The vector of siRNA-inhibited CDC2.SA expression and the negative control vector were constructed, sequenced and identified. Conclusion The successful construction and validation of the siRNA-inhibited CDC25A expression vector lays a good foundation for the next steps in CDC25A-related study.
出处 《中国癌症防治杂志》 CAS 2009年第2期101-104,共4页 CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT
基金 广西医疗卫生重点科研课题(重200866) 广西科学研究与技术开发计划项目(桂科攻0592007-1B) 广西研究生教育创新计划项目(2007105981002M 19)
关键词 CDC25A SIRNA 载体 CDC25A siRNA Vector
  • 相关文献

参考文献5

二级参考文献48

  • 1周丁华.肿瘤增殖力学研究的方法学[J].国外医学(肿瘤学分册),1995,22(3):136-138. 被引量:20
  • 2韩旻雁,银恭举,陈维清.中国人群鼻咽癌发病危险因素的Meta分析[J].中国热带医学,2005,5(7):1442-1443. 被引量:8
  • 3谭永红,杨晓霞,郑成位,雷新,单锦露,王东.3种分割式放疗对鼻咽癌患者远期疗效的比较[J].解放军医学杂志,2005,30(11):967-969. 被引量:2
  • 4程靖,姜捷.鼻咽癌患者血清和头发中微量元素的Meta分析[J].中国中西医结合耳鼻咽喉科杂志,2006,14(1):1-6. 被引量:5
  • 5肖婷婷,林汉生.中国南方地区鼻咽癌家族史危险因素的Meta分析[J].疾病控制杂志,2006,10(5):499-501. 被引量:4
  • 6Cox JD, Pajak TF, Marcial VA, et al. Dose-response for local control with hyperfractionated radiation therapy in advanced carcinoma of the upper aerodigestive tracts: preliminary report of Radiation Therapy Oncology Group Protocol 83-13 [ J ]. Int J Radiat Onco Biol Phys, 1990,18(3 ): 515-521.
  • 7Franchin G, Vaccher E, Talamini R, et al. Nasopharyngeal cancer WHO type Ⅱ -Ⅲ: monoinstitutional retrospective analysis with standard and accelerated hyperfractionated radiation therapy [ J ].Oral Oncology ,2002 ,38 ( 2 ) : 137-144.
  • 8Teo PML, Kwan WH, Leung SF, et al. Early tumor response and treatment toxicity after hyperfracionated radiotherapy in nasopharyngeal carcinoma[ J]. Br J Radiol,1996,69(819) :241-248.
  • 9Teo PML, Leung SF, Chan ATC, et al. Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant Increase in neurologic complications [ J ]. Int J Radiat Onco Biol Phys, 2000,48(5) :1311-1322.
  • 10Zhang EP,Lian PG,Cai KL,et al.Radiation therapy of nasopharyngeal carcinoma:prognostic factors based on a 10-year follow-up of 1302 patients.Int J Radiat Oncol Biol Phys,1989,16:301-305.

共引文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部